Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITIZENS FINANCIAL GROUP INC/RICFG · Entity 1913 | Director | February 14, 2019 | February 15, 2019 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITIZENS FINANCIAL GROUP INC/RI
Report date February 14, 2019 · Filed February 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,993.604 |
Reported balance
After 2019-02-14 transaction · row 1
1 source rowRow 1 · 2019-02-14 · Grant · Acquired 30.91 · Balance 60,993.604 F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted stock units credited to the reporting person's account following the issuer's dividend payment, pursuant to an award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan.
REGENERON PHARMACEUTICALS, INC.
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,303 |
Reported balance
After 2026-07-02 transaction · row 1
1 source rowRow 1 · 2026-07-02 · Sale · Disposed 200 · Balance 17,303 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025. F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.
F2: Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2017 Filed Feb 5, 2018 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-18-000008 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Read SEC document |
| May 05, 2017 Filed Feb 5, 2018 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-18-000008 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 20:39 UTC | CITIZENS FINANCIAL GROUP INC/RI CFG · Entity 1913 | GrantCommon Stock | 2,717 | $0.00 | $0.00 |
DisclosureSEC source: 0000759944-17-000035 · wf-form4_149341194039182.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,495 F1 · shares: Reflects a restricted stock unit award granted to the filer pursuant to the Citizens Financial Group, Inc. 2014 Non-Employee Directors Compensation Plan. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,830 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000003 · edgardoc.xml · derivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,830 Underlying: Common Stock · 7,830 shares Expires 2027-01-03 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-16-000084 · edgardoc.xml · nonDerivative · entry 2 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,500 Read SEC document |
| November 15, 2016 Filed Nov 16, 2016 21:21 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,000 | $429.34 | $858,680.00 |
DisclosureSEC source: 0001237899-16-000084 · edgardoc.xml · nonDerivative · entry 1 RYAN ARTHUR F · CIK 0001187443 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.